Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19
Chunmei Xie,1,* Qing Li,1,* Linhai Li,2,3,* Xiaohua Peng,4,5,* Zhijian Ling,1 Bin Xiao,3 Jingjing Feng,4,6 Zhenhong Chen,7 De Chang,2,8 Lixin Xie,2 Charles S Dela Cruz,4 Lokesh Sharma4 1Department of Blood Transfusion, Guangzhou 8th People’s Hospital, Guangzhou Medical University, Guangzho...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d9bcb77110a24d5c96620777d96fc433 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d9bcb77110a24d5c96620777d96fc433 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
covid-19 sars-cov-2 early inflammation asymptomatic patient elder patient Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
covid-19 sars-cov-2 early inflammation asymptomatic patient elder patient Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Xie C Li Q Li L Peng X Ling Z Xiao B Feng J Chen Z Chang D Xie L Dela Cruz CS Sharma L Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19 |
| description |
Chunmei Xie,1,* Qing Li,1,* Linhai Li,2,3,* Xiaohua Peng,4,5,* Zhijian Ling,1 Bin Xiao,3 Jingjing Feng,4,6 Zhenhong Chen,7 De Chang,2,8 Lixin Xie,2 Charles S Dela Cruz,4 Lokesh Sharma4 1Department of Blood Transfusion, Guangzhou 8th People’s Hospital, Guangzhou Medical University, Guangzhou, 510440, People’s Republic of China; 2College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing, 100083, People’s Republic of China; 3Department of Laboratory Medicine, General Hospital of Southern Theatre Command of PLA, Guangzhou, 510010, People’s Republic of China; 4Section of Pulmonary and Critical Care and Sleep Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA; 5Department of Rehabilitation Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People’s Republic of China; 6Department of Pulmonary and Critical Care Medicine, Shanghai Fifth People’s Hospital, Fudan University, Shanghai, 200240, People’s Republic of China; 7Department of Pulmonary and Critical Care Medicine, Secondary Medical Center, Chinese PLA General Hospital, Beijing, 100083, People’s Republic of China; 8 Department of Pulmonary and Critical Care Medicine, Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lixin Xie; De Chang Email 2464277169@qq.com; changde5501@foxmail.comBackground: Disease severity in COVID-19 ranges from asymptomatic infection to severe disease and death, especially in older subjects. The risk for severe infection and death has been reported to be 2X in those between 30 and 40 years, 3X in those between 40 and 50 years, and 4X in those between 50 and 65 years, compared to the reference group of 18– 29 years.Objective: To investigate the early changes in host immune responses that are altered with age and the difference in the early host inflammatory response that dictates a symptomatic versus asymptomatic course of COVID-19.Patients and Methods: COVID-19 subjects were identified by screening at the airport upon arrival from a foreign destination to China. Patients were either asymptomatic or had a mild disease when the first oro-pharyngeal (OP) swab samples were collected. Patients were quarantined and blood and throat swabs were collected during the course of the disease, allowing identification of the earliest host response to COVID-19. These patients were followed until their OP sample turned COVID-19 negative.Results: Data were obtained from 126 PCR-confirmed COVID-19 patients. The blood samples were obtained within 48 days of qPCR confirmation of viral infection. Older subjects (> 30 years) had significantly elevated levels of anti-inflammatory cytokine IL-10, a significant decrease in the percentage of CD8+ T cells, and expansion in NKT cell fraction. This was associated with significantly elevated viral load and a delayed humoral response in older subjects. Compared to symptomatic subjects, asymptomatic patients had an early increase in pro-inflammatory cytokine IL-2, while a decrease in both T regulatory cells and anti-inflammatory cytokine IL-10. Further, asymptomatic disease was associated with early humoral response and faster viral clearance.Conclusion: Early inflammatory response potentially plays a critical role for host-defense in COVID-19. The impaired early inflammatory response was associated with older age while a robust early inflammation was associated with asymptomatic disease.Keywords: COVID-19, SARS-CoV-2, early inflammation, asymptomatic patient, elder patient |
| format |
article |
| author |
Xie C Li Q Li L Peng X Ling Z Xiao B Feng J Chen Z Chang D Xie L Dela Cruz CS Sharma L |
| author_facet |
Xie C Li Q Li L Peng X Ling Z Xiao B Feng J Chen Z Chang D Xie L Dela Cruz CS Sharma L |
| author_sort |
Xie C |
| title |
Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19 |
| title_short |
Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19 |
| title_full |
Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19 |
| title_fullStr |
Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19 |
| title_full_unstemmed |
Association of Early Inflammation with Age and Asymptomatic Disease in COVID-19 |
| title_sort |
association of early inflammation with age and asymptomatic disease in covid-19 |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/d9bcb77110a24d5c96620777d96fc433 |
| work_keys_str_mv |
AT xiec associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT liq associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT lil associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT pengx associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT lingz associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT xiaob associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT fengj associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT chenz associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT changd associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT xiel associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT delacruzcs associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 AT sharmal associationofearlyinflammationwithageandasymptomaticdiseaseincovid19 |
| _version_ |
1718392054175760384 |
| spelling |
oai:doaj.org-article:d9bcb77110a24d5c96620777d96fc4332021-12-02T14:06:16ZAssociation of Early Inflammation with Age and Asymptomatic Disease in COVID-191178-7031https://doaj.org/article/d9bcb77110a24d5c96620777d96fc4332021-03-01T00:00:00Zhttps://www.dovepress.com/association-of-early-inflammation-with-age-and-asymptomatic-disease-in-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Chunmei Xie,1,* Qing Li,1,* Linhai Li,2,3,* Xiaohua Peng,4,5,* Zhijian Ling,1 Bin Xiao,3 Jingjing Feng,4,6 Zhenhong Chen,7 De Chang,2,8 Lixin Xie,2 Charles S Dela Cruz,4 Lokesh Sharma4 1Department of Blood Transfusion, Guangzhou 8th People’s Hospital, Guangzhou Medical University, Guangzhou, 510440, People’s Republic of China; 2College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing, 100083, People’s Republic of China; 3Department of Laboratory Medicine, General Hospital of Southern Theatre Command of PLA, Guangzhou, 510010, People’s Republic of China; 4Section of Pulmonary and Critical Care and Sleep Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT, 06520, USA; 5Department of Rehabilitation Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People’s Republic of China; 6Department of Pulmonary and Critical Care Medicine, Shanghai Fifth People’s Hospital, Fudan University, Shanghai, 200240, People’s Republic of China; 7Department of Pulmonary and Critical Care Medicine, Secondary Medical Center, Chinese PLA General Hospital, Beijing, 100083, People’s Republic of China; 8 Department of Pulmonary and Critical Care Medicine, Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lixin Xie; De Chang Email 2464277169@qq.com; changde5501@foxmail.comBackground: Disease severity in COVID-19 ranges from asymptomatic infection to severe disease and death, especially in older subjects. The risk for severe infection and death has been reported to be 2X in those between 30 and 40 years, 3X in those between 40 and 50 years, and 4X in those between 50 and 65 years, compared to the reference group of 18– 29 years.Objective: To investigate the early changes in host immune responses that are altered with age and the difference in the early host inflammatory response that dictates a symptomatic versus asymptomatic course of COVID-19.Patients and Methods: COVID-19 subjects were identified by screening at the airport upon arrival from a foreign destination to China. Patients were either asymptomatic or had a mild disease when the first oro-pharyngeal (OP) swab samples were collected. Patients were quarantined and blood and throat swabs were collected during the course of the disease, allowing identification of the earliest host response to COVID-19. These patients were followed until their OP sample turned COVID-19 negative.Results: Data were obtained from 126 PCR-confirmed COVID-19 patients. The blood samples were obtained within 48 days of qPCR confirmation of viral infection. Older subjects (> 30 years) had significantly elevated levels of anti-inflammatory cytokine IL-10, a significant decrease in the percentage of CD8+ T cells, and expansion in NKT cell fraction. This was associated with significantly elevated viral load and a delayed humoral response in older subjects. Compared to symptomatic subjects, asymptomatic patients had an early increase in pro-inflammatory cytokine IL-2, while a decrease in both T regulatory cells and anti-inflammatory cytokine IL-10. Further, asymptomatic disease was associated with early humoral response and faster viral clearance.Conclusion: Early inflammatory response potentially plays a critical role for host-defense in COVID-19. The impaired early inflammatory response was associated with older age while a robust early inflammation was associated with asymptomatic disease.Keywords: COVID-19, SARS-CoV-2, early inflammation, asymptomatic patient, elder patientXie CLi QLi LPeng XLing ZXiao BFeng JChen ZChang DXie LDela Cruz CSSharma LDove Medical Pressarticlecovid-19sars-cov-2early inflammationasymptomatic patientelder patientPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 1207-1216 (2021) |